A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

The randomised, double-blind and placebo-controlled trial involved 35 healthy participants, who were each given a single ...

Tocilizumab treatments in patients with noninfectious uveitis demonstrated high rates of success at 1 year follow ups.

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in overweight patients with cardiovascular disease.

Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.

Johnson & Johnson announced the submission of regulatory applications to the U.S. FDA and European Medicines Agency seeking approval of a ...

FinGo is expected to complement SMX’s tracing and authentication from source through its Human Identity-as-a-Service (HIDaaS) ...

Related: Ozempic (Semaglutide) - Subcutaneous When a drug is on the FDA shortage list, compounding pharmacies can legally mix ...

According to Nova One Advisor, the global Subcutaneous Drug Delivery Devices market size is calculated at 24.00 billion in 2024 and is projected to surpass USD 47.88 billion by 2033 with a remarkable ...

We have seen a number of dynamic changes in MDS over the last few years, and integrating them into our treatment paradigm will impact our approach, and perhaps offer a glimpse into the future." ...